New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
04:55 EDTOMED, OMED, OMED, MACK, MACK, MACK, KPTI, KPTI, KPTIAmerican Gastroenterological Association to hold a symposium
2014 Gastrointestinal Cancers Symposium is being held in San Francisco on January 16-18.
News For OMED;MACK;KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
05:20 EDTMACKPharmaEngine, Merrimack receive FDA fast track designation for MM-398
PharmaEngine and its partner Merrimack Pharmaceuticals (MACK) announced that MM-398 has been granted the Fast Track designation by the FDA for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Merrimack expects to begin the NDA submission in 2014.
November 19, 2014
09:16 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTMACKMerrimack receives FDA fast track designation for MM-398
Subscribe for More Information
07:54 EDTOMEDOncoMed presents biomarker-focused clinical data from Anti-Notch1 Phase 1a trial
Subscribe for More Information
November 18, 2014
07:20 EDTMACKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 13, 2014
09:15 EDTMACKMerrimack to present advances on targeted cancer molecules
Merrimack Pharmaceuticals announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
November 12, 2014
07:53 EDTOMEDLeerink to hold a tour
Subscribe for More Information
November 11, 2014
08:05 EDTMACKMerrimack shares should be bought on weakness, says Oppenheimer
After Merrimack announced a delay of about one quarter for the NDA submission of its MM-398, Oppenheimer's concern about the issue is limited. The firm says that the FDA appears to be interested in ensuring that MM-398 has extended nanoparticle stability, but does not appear to have identified a material deficit in the company's chemistry, manufacturing, and controls. Oppenheimer keeps an $11 price target and Outperform rating on Merrimack.
November 10, 2014
16:09 EDTMACKMerrimack reports Q3 EPS (27c), consensus (12c)
Subscribe for More Information
10:04 EDTKPTIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:27 EDTKPTIKaryopharm initiates clinical study of Selinexor
Subscribe for More Information
07:26 EDTKPTIKaryopharm sees existing cash, cash equivalents to fund R&D into 2H17
Karyopharm expects to end 2014 with greater than $200M in cash and cash equivalents.
07:26 EDTKPTIKaryopharm reports Q3 EPS (61c), consensus (52c)
Subscribe for More Information
07:18 EDTKPTIKaryopharm upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use